Global Oncology Drugs Market 2018-2024
Global Oncology Drugs Market – Drivers, Restraints, Opportunities, Trends, and Forecasts: 2018–2024
Overview: Oncology drugs or anti-cancer drugs or anti-neoplastic drugs are agents that can be used alone or in combination to control or destroy neoplastic cells. These agents can be either systemic or targeted. In systemic, the drug spreads throughout the body, whereas in targeted, the drug or substance identifies the specific location causing less harm to the growth of neighboring healthy cells. The oncology drugs market, by applications, is segmented into breast cancer, blood cancer, prostate cancer, gastrointestinal cancer, lung cancer, and others. The incidence of cancer is one of the leading causes of death globally due to unhealthy food habits, changing lifestyle, and increasing consumption of tobacco-related products. According to the estimation of the National Cancer Institute, in the US, around 1.6 million new cases of cancer were diagnosed and 595,690 people died due to cancer in 2016. Nearly 60% of new cancer cases are from Africa, Asia, Central and South American countries and almost 70% of cancer deaths are from these regions. The Indian Council for Medical Research estimated around 1.4 million new cancer cases in 2016, which is expected to rise to 1.7 million cases by 2020.
Increased prevalence of cancer, unhealthy lifestyle, and increasing geriatric population are the primary factors driving the market growth. However, the high cost of the drug & development process and side effects of the drug are the factors hampering the market growth. The development of pipeline oncology products and expiry of key patents are providing an opportunity for the manufacturers of cancer drugs.
Market Analysis: The global oncology drugs market is estimated to witness a CAGR of 7.0% during the forecast period 2018–2024. The market is analyzed based on three segments: therapeutic modality, applications, and regions.
Regional Analysis: The regions covered in the report are North America, Europe, Asia Pacific, and Rest of the World (RoW). North America is set to be the leading region for the oncology drugs market growth followed by Europe, Asia Pacific, and Rest of the World.
Therapeutic Modality Analysis: The global oncology drugs market by therapeutic modality is segmented into chemotherapy, immunotherapy, targeted therapy, and others. Chemotherapy occupied the largest share in 2017, and immunotherapy is expected to grow at a high CAGR in the coming years due to high efficiency, increased preference of targeted immunotherapy from chemotherapy, and fewer side effects.
Applications Analysis: The global oncology drugs market by applications is segmented into breast cancer, blood cancer, prostate cancer, gastrointestinal cancer, lung cancer, and others. Blood cancer occupied the largest share in 2017, and lung cancer application is expected to be the fastest growing segment during the forecast period due to the high incidence of lung cancer and promising pipeline for NSCLC drugs.
Key Players: F. Hoffmann-La Roche Ltd., Bristol–Myers Squibb, Novartis AG, Johnson & Johnson, Pfizer, Inc., Celgene Corporation, AstraZeneca PLC, GlaxoSmithKline plc, Eli Lilly and Company, Amgen Inc., Merck & Co., AbbVie, Inc., Sanofi, and other predominate & niche players.
Competitive Analysis: The high adoption of personalized medicine and immuno-oncology have fueled a shift in cancer treatment from chemotherapy in the past decade. During 2011–2017, around 84 new drugs have been approved across 22 indications globally, of which immuno-oncology PD-1 and PD-L1 inhibitors have seen a speedy uptake based on their notable clinical profile and approval for various cancers. Additionally, there is a robust late-stage oncology pipeline with around 630 unique molecules in the development, i.e., more than 7% when compared to the previous year, including 278 biological therapies and 82 vaccines. The market is dominated by key vendors such as F. Hoffmann-La Roche Ltd., Bristol–Myers Squibb, Novartis AG, Celgene Corporation, Pfizer Inc., and Johnson & Johnson; and products of these firms are available globally through their distributors and subsidiaries.
Benefits: The report provides complete details about the usage and adoption of oncology drugs in various applications and regions. With that, key stakeholders can know about the major trends, drivers, investments, vertical player’s initiatives, government initiatives toward the product adoption in the upcoming years along with the details of commercial products available in the market. Moreover, the report provides details about the major challenges that are going to impact on the market growth. Additionally, the report gives the complete details about the key business opportunities to key stakeholders to expand their business and capture the revenue in specific verticals to analyze before investing or expanding the business in this market.
Key Stakeholders:
Overview: Oncology drugs or anti-cancer drugs or anti-neoplastic drugs are agents that can be used alone or in combination to control or destroy neoplastic cells. These agents can be either systemic or targeted. In systemic, the drug spreads throughout the body, whereas in targeted, the drug or substance identifies the specific location causing less harm to the growth of neighboring healthy cells. The oncology drugs market, by applications, is segmented into breast cancer, blood cancer, prostate cancer, gastrointestinal cancer, lung cancer, and others. The incidence of cancer is one of the leading causes of death globally due to unhealthy food habits, changing lifestyle, and increasing consumption of tobacco-related products. According to the estimation of the National Cancer Institute, in the US, around 1.6 million new cases of cancer were diagnosed and 595,690 people died due to cancer in 2016. Nearly 60% of new cancer cases are from Africa, Asia, Central and South American countries and almost 70% of cancer deaths are from these regions. The Indian Council for Medical Research estimated around 1.4 million new cancer cases in 2016, which is expected to rise to 1.7 million cases by 2020.
Increased prevalence of cancer, unhealthy lifestyle, and increasing geriatric population are the primary factors driving the market growth. However, the high cost of the drug & development process and side effects of the drug are the factors hampering the market growth. The development of pipeline oncology products and expiry of key patents are providing an opportunity for the manufacturers of cancer drugs.
Market Analysis: The global oncology drugs market is estimated to witness a CAGR of 7.0% during the forecast period 2018–2024. The market is analyzed based on three segments: therapeutic modality, applications, and regions.
Regional Analysis: The regions covered in the report are North America, Europe, Asia Pacific, and Rest of the World (RoW). North America is set to be the leading region for the oncology drugs market growth followed by Europe, Asia Pacific, and Rest of the World.
Therapeutic Modality Analysis: The global oncology drugs market by therapeutic modality is segmented into chemotherapy, immunotherapy, targeted therapy, and others. Chemotherapy occupied the largest share in 2017, and immunotherapy is expected to grow at a high CAGR in the coming years due to high efficiency, increased preference of targeted immunotherapy from chemotherapy, and fewer side effects.
Applications Analysis: The global oncology drugs market by applications is segmented into breast cancer, blood cancer, prostate cancer, gastrointestinal cancer, lung cancer, and others. Blood cancer occupied the largest share in 2017, and lung cancer application is expected to be the fastest growing segment during the forecast period due to the high incidence of lung cancer and promising pipeline for NSCLC drugs.
Key Players: F. Hoffmann-La Roche Ltd., Bristol–Myers Squibb, Novartis AG, Johnson & Johnson, Pfizer, Inc., Celgene Corporation, AstraZeneca PLC, GlaxoSmithKline plc, Eli Lilly and Company, Amgen Inc., Merck & Co., AbbVie, Inc., Sanofi, and other predominate & niche players.
Competitive Analysis: The high adoption of personalized medicine and immuno-oncology have fueled a shift in cancer treatment from chemotherapy in the past decade. During 2011–2017, around 84 new drugs have been approved across 22 indications globally, of which immuno-oncology PD-1 and PD-L1 inhibitors have seen a speedy uptake based on their notable clinical profile and approval for various cancers. Additionally, there is a robust late-stage oncology pipeline with around 630 unique molecules in the development, i.e., more than 7% when compared to the previous year, including 278 biological therapies and 82 vaccines. The market is dominated by key vendors such as F. Hoffmann-La Roche Ltd., Bristol–Myers Squibb, Novartis AG, Celgene Corporation, Pfizer Inc., and Johnson & Johnson; and products of these firms are available globally through their distributors and subsidiaries.
Benefits: The report provides complete details about the usage and adoption of oncology drugs in various applications and regions. With that, key stakeholders can know about the major trends, drivers, investments, vertical player’s initiatives, government initiatives toward the product adoption in the upcoming years along with the details of commercial products available in the market. Moreover, the report provides details about the major challenges that are going to impact on the market growth. Additionally, the report gives the complete details about the key business opportunities to key stakeholders to expand their business and capture the revenue in specific verticals to analyze before investing or expanding the business in this market.
Key Stakeholders:
1 INDUSTRY OUTLOOK
1.1 Industry overview
1.2 Industry Trends
1.3 Total addressable market
1.4 Trends of cancer therapy market
2 REPORT OUTLINE
2.1 Report Scope
2.2 Report Summary
2.3 Research Methodology
2.4 Report Assumptions
3 MARKET SNAPSHOT
3.1 Market Definition – Infoholic Research
3.2 Segmented Addressable Market (SAM)
3.3 Trends of the oncology drugs market
3.4 Related Markets
3.4.1 Over the counter drugs (OTC)
3.4.2 Active pharmaceutical ingredients (APIs)
3.4.3 Diabetes Drugs
4 MARKET OUTLOOK
4.1 Oncology Drugs Approved by FDA (2014 – 2018)
4.2 Market segmentation
4.3 PEST Analysis
4.4 Porter 5(Five) Forces
5 MARKET CHARACTERISTICS
5.1 DRO – Global Oncology Drugs Market Dynamics
5.1.1 Drivers
5.1.1.1 Increasing incidence of cancer across the globe
5.1.1.2 Growing geriatric population
5.1.1.3 Expiration of patents
5.1.2 Opportunities
5.1.2.1 Growing focus on personalized medicine
5.1.2.2 Increasing healthcare spending
5.1.3 Restraints
5.1.3.1 High cost of the drug
5.1.3.2 Side effects of oncology drugs
6 THERAPEUTIC MODALITY: MARKET SIZE AND ANALYSIS
6.1 Overview
6.2 Chemotherapy
6.3 Targeted therapy
6.4 Immunotherapy
6.5 Others
7 APPLICATION: MARKET SIZE AND ANALYSIS
7.1 Overview
7.2 Blood cancer
7.3 Breast cancer
7.4 Gastro intestinal cancer
7.5 Lung cancer
7.6 Prostate cancer
7.7 Others
8 REGIONS: MARKET SIZE AND ANALYSIS
8.1 Overview
8.2 North America
8.2.1 Overview
8.2.2 US
8.2.3 Canada
8.3 Europe
8.3.1 Overview
8.3.2 UK
8.3.3 Germany
8.3.4 France
8.3.5 Italy
8.4 APAC
8.4.1 Overview
8.4.2 India
8.4.3 China
8.5 Rest of the World
9 COMPETITIVE LANDSCAPE
9.1 Overview
10 VENDOR PROFILES
10.1 F.Hoffmann-La Roche Ltd
10.1.1 Overview
10.1.2 Business Unit
10.1.3 Geographic Presence
10.1.4
10.1.5 Business Focus
10.1.6 SWOT Analysis
10.1.7 Business Strategy
10.2 Novartis AG
10.2.1 Overview
10.2.2 Business Unit
10.2.3 Geographic Presence
10.2.4 Business Focus
10.2.5 SWOT Analysis
10.2.6 Business Strategy
10.3 Bristol-Myers Squibb
10.3.1 Overview
10.3.2 Geographic Presence
10.3.3 Business Focus
10.3.4 SWOT Analysis
10.3.5 Business Strategy
10.4 Celgene Corporation
10.4.1 Overview
10.4.2 Geographic Presence
10.4.3 Business Focus
10.4.4 SWOT Analysis
10.4.5 Business Strategy
10.5 Johnson & Johnson
10.5.1 Overview
10.5.2 Business Units
10.5.3 Geographic Revenue
10.5.4 Business Focus
10.5.5 SWOT Analysis
10.5.6 Business Strategies
10.6 Pfizer Inc.,
10.6.1 Overview
10.6.2 Geographic Presence
10.6.3 Business Focus
10.6.4 SWOT Analysis
10.6.5 Business Strategies
11 COMPANIES TO WATCH FOR
11.1 Astra Zenca PLC
11.1.1 Overview
11.2 Eli Lilly and Company.
11.2.1 Overview
11.3 GlaxoSmithKline plc
11.3.1 Overview
11.4 Merck & Co.
11.4.1 Overview
11.5 Sanofi
11.5.1 Overview
11.6 Amgen Inc.
11.6.1 Overview
11.7 AbbVie, Inc.
11.7.1 Overview
12 ANNEXURE
12.1 Abbreviations
Tables
Table 1 GLOBAL ONCOLOGY DRUGS MARKET REVENUE BY REGIONS, 2017–2024 ($BILLION)
Table 1 GLOBAL ONCOLOGY DRUGS MARKET BY VENDOR RANKING, 2017
Table 2 OTHER PROMINENT VENDORS OF ONCOLOGY DRUGS MARKET
Table 3 F. HOFFMANN-LA ROCHE: OFFERINGS
Table 4 F. HOFFMANN-LA ROCHE: RECENT DEVELOPMENTS
Table 5 NOVARTIS AG: OFFERINGS
Table 6 NOVARTIS AG: RECENT DEVELOPMENTS
Table 7 BRISTOL-MYERS SQUIBB: OFFERINGS
Table 8 BRISTOL-MYERS SQUIBB: RECENT DEVELOPMENT
Table 9 CELGENE CORPORATION: OFFERINGS
Table 10 CELGENE CORPORATION: RECENT DEVELOPMENTS
Table 11 JOHNSON & JOHNSON: PRODUCT OFFERINGS
Table 12 JOHNSON & JOHNSON: RECENT DEVELOPMENTS
Table 13 PFIZER, INC.: PRODUCT OFFERINGS
Table 14 PFIZER INC.: RECENT DEVELOPMENTS
Table 15 ASTRA ZENECA PLC.: SNAPSHOT
Table 16 ASTRA ZENECA PLC: RECENT DEVELOPMENTS
Table 17 ELI LILLY AND COMPANY: SNAPSHOT
Table 18 ELI LILLY AND COMPANY: RECENT DEVELOPMENTS
Table 19 GLAXOSMITHKLINE PLC.: OVERVIEW
Table 20 GLAXOSMITHKLINE PLC: RECENT DEVELOPMENTS
Table 21 MERCK & CO: OVERVIEW
Table 22 MERCK & CO: RECENT DEVELOPMENTS
Table 23 SANOFI: SNAPSHOT
Table 24 SANOFI: RECENT DEVELOPMENTS
Table 25 AMGEN INC.: SNAPSHOT
Table 26 AMGEN INC: RECENT DEVELOPMENTS
Table 27 ABBVIE INC: SNAPSHOT
Table 28 ABBVIE INC: RECENT DEVELOPMENTS
Charts
Chart 1 RESEARCH METHODOLOGY OF GLOBAL ONCOLOGY DRUGS MARKET
Chart 2 GLOBAL ONCOLOGY DRUGS MARKET REVENUE, 2017–2024 ($BILLION)
Chart 3 NUMBER OF ONCOLOGY DRUGS APPROVED FROM 2014-2017
Chart 4 SEGMENTATION OF GLOBAL ONCOLOGY DRUGS MARKET
Chart 5 PEST ANALYSIS OF GLOBAL ONCOLOGY DRUGS MARKET
Chart 6 PORTER 5 FORCES ON GLOBAL ONCOLOGY DRUGS MARKET
Chart 7 DRO – IMPACT ANALYSIS OF GLOBAL ONCOLOGY DRUGS MARKET
Chart 8 KEY STAKEHOLDERS
Chart 9 GLOBAL ONCOLOGY DRUGS MARKET BY THERAPEUTIC MODALITY SEGMENTATION, 2017 (%)
Chart 10 GLOBAL ONCOLOGY DRUGS MARKET BY THERAPEUTIC MODALITY SEGMENTATION, 2024 (%)
Chart 11 GLOBAL CHEMOTHERAPY MARKET FORECAST, 2017–2024 ($BILLION)
Chart 12 GLOBAL TARGETED THERAPY MARKET FORECAST, 2017–2024 ($BILLION)
Chart 13 GLOBAL IMMUNOTHERAPY MARKET FORECAST, 2017–2024 ($BILLION)
Chart 14 GLOBAL OTHERS MARKET FORECAST, 2017–2024 ($BILLION)
Chart 15 GLOBAL ONCOLOGY DRUGS MARKET BY APPLICATION SEGMENTATION, 2017 (%)
Chart 16 GLOBAL ONCOLOGY DRUGS MARKET BY GEOGRAPHICAL SEGMENTATION, 2017 (%)
Chart 17 ONCOLOGY DRUGS MARKET REVENUE IN NORTH AMERICA, 2017–2024 ($BILLION)
Chart 18 ONCOLOGY DRUGS MARKET REVENUE IN EUROPE, 2017–2024 ($BILLION)
Chart 19 ONCOLOGY DRUGS REVENUE IN ASIA-PACIFIC, 2017–2024 ($BILLION)
Chart 20 ONCOLOGY DRUGS MARKET REVENUE IN REST OF THE WORLD, 2017–2024 ($BILLION)
Chart 25 NOVARTIS AG: OVERVIEW SNAPSHOT
Chart 26 NOVARTIS AG: BUSINESS UNITS
Chart 27 NOVARTIS GA: GEOGRAPHICAL PRESENCE
Chart 28 NOVARTIS AG: SWOT ANALYSIS
Chart 29 BRISTOL-MYERS SQUIBB.: OVERVIEW SNAPSHOT
Chart 30 BRISTOL-MYERS SQUIBB.: BUSINESS SEGMENTS
Chart 31 BRISTOL-MYERS SQUIBB.: GEOGRAPHIC PRESENCE
Chart 32 BRISTOL-MYERS SQUIBB.: SWOT ANALYSIS
Chart 33 CELGENE CORPORATION: OVERVIEW SNAPSHOT
Chart 34 CELGENE CORPORATION: GEOGRAPHIC PRESENCE
Chart 35 CELGENE CORPORATION: SWOT ANALYSIS
Chart 36 JOHNSON & JOHNSON: OVERVIEW SNAPSHOT
Chart 37 JOHNSON & JOHNSON: BUSINESS UNITS
Chart 38 JOHNSON & JOHNSON: GEOGRAPHIC REVENUE
Chart 39 JOHNSON & JOHNSON: SWOT ANALYSIS
Chart 40 PFIZER INC.,: OVERVIEW SNAPSHOT
Chart 41 PFIZER INC.: BUSINESS UNITS REVENUE
Chart 42 PFIZER INC.: GEOGRAPHICAL PRESENCE
Chart 43 PFIZER INC.: SWOT ANALYSIS
1.1 Industry overview
1.2 Industry Trends
1.3 Total addressable market
1.4 Trends of cancer therapy market
2 REPORT OUTLINE
2.1 Report Scope
2.2 Report Summary
2.3 Research Methodology
2.4 Report Assumptions
3 MARKET SNAPSHOT
3.1 Market Definition – Infoholic Research
3.2 Segmented Addressable Market (SAM)
3.3 Trends of the oncology drugs market
3.4 Related Markets
3.4.1 Over the counter drugs (OTC)
3.4.2 Active pharmaceutical ingredients (APIs)
3.4.3 Diabetes Drugs
4 MARKET OUTLOOK
4.1 Oncology Drugs Approved by FDA (2014 – 2018)
4.2 Market segmentation
4.3 PEST Analysis
4.4 Porter 5(Five) Forces
5 MARKET CHARACTERISTICS
5.1 DRO – Global Oncology Drugs Market Dynamics
5.1.1 Drivers
5.1.1.1 Increasing incidence of cancer across the globe
5.1.1.2 Growing geriatric population
5.1.1.3 Expiration of patents
5.1.2 Opportunities
5.1.2.1 Growing focus on personalized medicine
5.1.2.2 Increasing healthcare spending
5.1.3 Restraints
5.1.3.1 High cost of the drug
5.1.3.2 Side effects of oncology drugs
6 THERAPEUTIC MODALITY: MARKET SIZE AND ANALYSIS
6.1 Overview
6.2 Chemotherapy
6.3 Targeted therapy
6.4 Immunotherapy
6.5 Others
7 APPLICATION: MARKET SIZE AND ANALYSIS
7.1 Overview
7.2 Blood cancer
7.3 Breast cancer
7.4 Gastro intestinal cancer
7.5 Lung cancer
7.6 Prostate cancer
7.7 Others
8 REGIONS: MARKET SIZE AND ANALYSIS
8.1 Overview
8.2 North America
8.2.1 Overview
8.2.2 US
8.2.3 Canada
8.3 Europe
8.3.1 Overview
8.3.2 UK
8.3.3 Germany
8.3.4 France
8.3.5 Italy
8.4 APAC
8.4.1 Overview
8.4.2 India
8.4.3 China
8.5 Rest of the World
9 COMPETITIVE LANDSCAPE
9.1 Overview
10 VENDOR PROFILES
10.1 F.Hoffmann-La Roche Ltd
10.1.1 Overview
10.1.2 Business Unit
10.1.3 Geographic Presence
10.1.4
10.1.5 Business Focus
10.1.6 SWOT Analysis
10.1.7 Business Strategy
10.2 Novartis AG
10.2.1 Overview
10.2.2 Business Unit
10.2.3 Geographic Presence
10.2.4 Business Focus
10.2.5 SWOT Analysis
10.2.6 Business Strategy
10.3 Bristol-Myers Squibb
10.3.1 Overview
10.3.2 Geographic Presence
10.3.3 Business Focus
10.3.4 SWOT Analysis
10.3.5 Business Strategy
10.4 Celgene Corporation
10.4.1 Overview
10.4.2 Geographic Presence
10.4.3 Business Focus
10.4.4 SWOT Analysis
10.4.5 Business Strategy
10.5 Johnson & Johnson
10.5.1 Overview
10.5.2 Business Units
10.5.3 Geographic Revenue
10.5.4 Business Focus
10.5.5 SWOT Analysis
10.5.6 Business Strategies
10.6 Pfizer Inc.,
10.6.1 Overview
10.6.2 Geographic Presence
10.6.3 Business Focus
10.6.4 SWOT Analysis
10.6.5 Business Strategies
11 COMPANIES TO WATCH FOR
11.1 Astra Zenca PLC
11.1.1 Overview
11.2 Eli Lilly and Company.
11.2.1 Overview
11.3 GlaxoSmithKline plc
11.3.1 Overview
11.4 Merck & Co.
11.4.1 Overview
11.5 Sanofi
11.5.1 Overview
11.6 Amgen Inc.
11.6.1 Overview
11.7 AbbVie, Inc.
11.7.1 Overview
12 ANNEXURE
12.1 Abbreviations
Tables
Table 1 GLOBAL ONCOLOGY DRUGS MARKET REVENUE BY REGIONS, 2017–2024 ($BILLION)
Table 1 GLOBAL ONCOLOGY DRUGS MARKET BY VENDOR RANKING, 2017
Table 2 OTHER PROMINENT VENDORS OF ONCOLOGY DRUGS MARKET
Table 3 F. HOFFMANN-LA ROCHE: OFFERINGS
Table 4 F. HOFFMANN-LA ROCHE: RECENT DEVELOPMENTS
Table 5 NOVARTIS AG: OFFERINGS
Table 6 NOVARTIS AG: RECENT DEVELOPMENTS
Table 7 BRISTOL-MYERS SQUIBB: OFFERINGS
Table 8 BRISTOL-MYERS SQUIBB: RECENT DEVELOPMENT
Table 9 CELGENE CORPORATION: OFFERINGS
Table 10 CELGENE CORPORATION: RECENT DEVELOPMENTS
Table 11 JOHNSON & JOHNSON: PRODUCT OFFERINGS
Table 12 JOHNSON & JOHNSON: RECENT DEVELOPMENTS
Table 13 PFIZER, INC.: PRODUCT OFFERINGS
Table 14 PFIZER INC.: RECENT DEVELOPMENTS
Table 15 ASTRA ZENECA PLC.: SNAPSHOT
Table 16 ASTRA ZENECA PLC: RECENT DEVELOPMENTS
Table 17 ELI LILLY AND COMPANY: SNAPSHOT
Table 18 ELI LILLY AND COMPANY: RECENT DEVELOPMENTS
Table 19 GLAXOSMITHKLINE PLC.: OVERVIEW
Table 20 GLAXOSMITHKLINE PLC: RECENT DEVELOPMENTS
Table 21 MERCK & CO: OVERVIEW
Table 22 MERCK & CO: RECENT DEVELOPMENTS
Table 23 SANOFI: SNAPSHOT
Table 24 SANOFI: RECENT DEVELOPMENTS
Table 25 AMGEN INC.: SNAPSHOT
Table 26 AMGEN INC: RECENT DEVELOPMENTS
Table 27 ABBVIE INC: SNAPSHOT
Table 28 ABBVIE INC: RECENT DEVELOPMENTS
Charts
Chart 1 RESEARCH METHODOLOGY OF GLOBAL ONCOLOGY DRUGS MARKET
Chart 2 GLOBAL ONCOLOGY DRUGS MARKET REVENUE, 2017–2024 ($BILLION)
Chart 3 NUMBER OF ONCOLOGY DRUGS APPROVED FROM 2014-2017
Chart 4 SEGMENTATION OF GLOBAL ONCOLOGY DRUGS MARKET
Chart 5 PEST ANALYSIS OF GLOBAL ONCOLOGY DRUGS MARKET
Chart 6 PORTER 5 FORCES ON GLOBAL ONCOLOGY DRUGS MARKET
Chart 7 DRO – IMPACT ANALYSIS OF GLOBAL ONCOLOGY DRUGS MARKET
Chart 8 KEY STAKEHOLDERS
Chart 9 GLOBAL ONCOLOGY DRUGS MARKET BY THERAPEUTIC MODALITY SEGMENTATION, 2017 (%)
Chart 10 GLOBAL ONCOLOGY DRUGS MARKET BY THERAPEUTIC MODALITY SEGMENTATION, 2024 (%)
Chart 11 GLOBAL CHEMOTHERAPY MARKET FORECAST, 2017–2024 ($BILLION)
Chart 12 GLOBAL TARGETED THERAPY MARKET FORECAST, 2017–2024 ($BILLION)
Chart 13 GLOBAL IMMUNOTHERAPY MARKET FORECAST, 2017–2024 ($BILLION)
Chart 14 GLOBAL OTHERS MARKET FORECAST, 2017–2024 ($BILLION)
Chart 15 GLOBAL ONCOLOGY DRUGS MARKET BY APPLICATION SEGMENTATION, 2017 (%)
Chart 16 GLOBAL ONCOLOGY DRUGS MARKET BY GEOGRAPHICAL SEGMENTATION, 2017 (%)
Chart 17 ONCOLOGY DRUGS MARKET REVENUE IN NORTH AMERICA, 2017–2024 ($BILLION)
Chart 18 ONCOLOGY DRUGS MARKET REVENUE IN EUROPE, 2017–2024 ($BILLION)
Chart 19 ONCOLOGY DRUGS REVENUE IN ASIA-PACIFIC, 2017–2024 ($BILLION)
Chart 20 ONCOLOGY DRUGS MARKET REVENUE IN REST OF THE WORLD, 2017–2024 ($BILLION)
Chart 25 NOVARTIS AG: OVERVIEW SNAPSHOT
Chart 26 NOVARTIS AG: BUSINESS UNITS
Chart 27 NOVARTIS GA: GEOGRAPHICAL PRESENCE
Chart 28 NOVARTIS AG: SWOT ANALYSIS
Chart 29 BRISTOL-MYERS SQUIBB.: OVERVIEW SNAPSHOT
Chart 30 BRISTOL-MYERS SQUIBB.: BUSINESS SEGMENTS
Chart 31 BRISTOL-MYERS SQUIBB.: GEOGRAPHIC PRESENCE
Chart 32 BRISTOL-MYERS SQUIBB.: SWOT ANALYSIS
Chart 33 CELGENE CORPORATION: OVERVIEW SNAPSHOT
Chart 34 CELGENE CORPORATION: GEOGRAPHIC PRESENCE
Chart 35 CELGENE CORPORATION: SWOT ANALYSIS
Chart 36 JOHNSON & JOHNSON: OVERVIEW SNAPSHOT
Chart 37 JOHNSON & JOHNSON: BUSINESS UNITS
Chart 38 JOHNSON & JOHNSON: GEOGRAPHIC REVENUE
Chart 39 JOHNSON & JOHNSON: SWOT ANALYSIS
Chart 40 PFIZER INC.,: OVERVIEW SNAPSHOT
Chart 41 PFIZER INC.: BUSINESS UNITS REVENUE
Chart 42 PFIZER INC.: GEOGRAPHICAL PRESENCE
Chart 43 PFIZER INC.: SWOT ANALYSIS
